{"id":11050,"date":"2026-03-02T22:09:40","date_gmt":"2026-03-02T21:09:40","guid":{"rendered":"https:\/\/valintermed.com\/?p=11050"},"modified":"2026-03-02T22:09:40","modified_gmt":"2026-03-02T21:09:40","slug":"evnuhoidizm-semeynyy-gipogonadotropnyy","status":"publish","type":"post","link":"https:\/\/valintermed.com\/en\/medlibrary\/evnuhoidism-family-hypogonadotropic\/","title":{"rendered":"Eunuchoidism Familial Hypogonadotropic"},"content":{"rendered":"<div class=\"fpm_start\"><\/div>\n<p>Familial hypogonadotropic eunuchoidism is a rare congenital endocrine disorder in which normal development of the genital organs and secondary sexual characteristics is disrupted due to insufficient production of gonadotropin-releasing hormone (GnRH) by the hypothalamus. This leads to suppression of the secretion of follicle-stimulating (FSH) and luteinizing (LH) hormones by the pituitary gland, resulting in hypogonadism with low testosterone levels in men or estrogens in women. Unlike other forms of hypogonadism, the gonadal tissue itself remains structurally intact and potentially functional \u2014 the problem lies \"higher up,\" in central regulation. In men, this manifests as delayed puberty, tall stature with \"long-nosed\" proportions, lack of male-pattern hair growth, small testicles, a poorly developed voice, and consequently, infertility. In women \u2014 primary amenorrhea, absence of mammary glands, virgin form of external genitalia. At the same time, intelligence and psycho-emotional development are usually unaffected. It is important to understand: this is not a \"weakness of character\" or a result of trauma \u2014 it is a genetically determined pathology that requires precise diagnosis and timely treatment.<\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_86 counter-flat ez-toc-counter ez-toc-light-blue ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Content<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewbox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewbox=\"0 0 24 24\" version=\"1.2\" baseprofile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 eztoc-toggle-hide-by-default' ><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/evnuhoidism-family-hypogonadotropic\/#%D0%9A%D0%BB%D0%B0%D1%81%D1%81%D0%B8%D1%84%D0%B8%D0%BA%D0%B0%D1%86%D0%B8%D1%8F_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F_%D0%BF%D0%BE_%D0%9C%D0%9A%D0%91-10_%D0%B8_%D0%9C%D0%9A%D0%91-11\" >Classification of the disease according to ICD-10 and ICD-11<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/evnuhoidism-family-hypogonadotropic\/#%D0%98%D1%81%D1%82%D0%BE%D1%80%D0%B8%D1%8F_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F_%D0%B8_%D0%B8%D0%BD%D1%82%D0%B5%D1%80%D0%B5%D1%81%D0%BD%D1%8B%D0%B5_%D0%B8%D1%81%D1%82%D0%BE%D1%80%D0%B8%D1%87%D0%B5%D1%81%D0%BA%D0%B8%D0%B5_%D1%84%D0%B0%D0%BA%D1%82%D1%8B\" >History of the disease and interesting historical facts<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/evnuhoidism-family-hypogonadotropic\/#%D0%AD%D0%BF%D0%B8%D0%B4%D0%B5%D0%BC%D0%B8%D0%BE%D0%BB%D0%BE%D0%B3%D0%B8%D1%8F_%D0%BD%D0%B0%D1%81%D0%BA%D0%BE%D0%BB%D1%8C%D0%BA%D0%BE_%D1%87%D0%B0%D1%81%D1%82%D0%BE_%D0%B2%D1%81%D1%82%D1%80%D0%B5%D1%87%D0%B0%D0%B5%D1%82%D1%81%D1%8F_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D0%B5\" >Epidemiology: how common is the disease?<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/evnuhoidism-family-hypogonadotropic\/#%D0%93%D0%B5%D0%BD%D0%B5%D1%82%D0%B8%D1%87%D0%B5%D1%81%D0%BA%D0%B0%D1%8F_%D0%BF%D1%80%D0%B5%D0%B4%D1%80%D0%B0%D1%81%D0%BF%D0%BE%D0%BB%D0%BE%D0%B6%D0%B5%D0%BD%D0%BD%D0%BE%D1%81%D1%82%D1%8C_%D0%BA%D0%B0%D0%BA%D0%B8%D0%B5_%D0%B3%D0%B5%D0%BD%D1%8B_%C2%AB%D0%B2%D0%B8%D0%BD%D0%BE%D0%B2%D0%B0%D1%82%D1%8B%C2%BB\" >Genetic predisposition: which genes are \"guilty\"?<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/evnuhoidism-family-hypogonadotropic\/#%D0%A4%D0%B0%D0%BA%D1%82%D0%BE%D1%80%D1%8B_%D1%80%D0%B8%D1%81%D0%BA%D0%B0_%D1%87%D1%82%D0%BE_%D0%BC%D0%BE%D0%B6%D0%B5%D1%82_%D1%81%D0%BF%D1%80%D0%BE%D0%B2%D0%BE%D1%86%D0%B8%D1%80%D0%BE%D0%B2%D0%B0%D1%82%D1%8C_%D0%B8%D0%BB%D0%B8_%D1%83%D1%81%D1%83%D0%B3%D1%83%D0%B1%D0%B8%D1%82%D1%8C_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D0%B5\" >Risk factors: what can provoke or exacerbate the disease?<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/evnuhoidism-family-hypogonadotropic\/#%D0%94%D0%B8%D0%B0%D0%B3%D0%BD%D0%BE%D1%81%D1%82%D0%B8%D0%BA%D0%B0_%D0%BA%D0%B0%D0%BA_%D1%80%D0%B0%D1%81%D0%BF%D0%BE%D0%B7%D0%BD%D0%B0%D1%82%D1%8C_%D0%92%D0%93%D0%93_%D0%B8_%D0%BE%D1%82%D0%BB%D0%B8%D1%87%D0%B8%D1%82%D1%8C_%D0%BE%D1%82_%D0%B4%D1%80%D1%83%D0%B3%D0%B8%D1%85_%D1%81%D0%BE%D1%81%D1%82%D0%BE%D1%8F%D0%BD%D0%B8%D0%B9h2%3E_%D0%94%D0%B8%D0%B0%D0%B3%D0%BD%D0%BE%D0%B7_%D1%81%D1%82%D0%B0%D0%B2%D0%B8%D1%82%D1%81%D1%8F_%D0%BA%D0%BE%D0%BC%D0%BF%D0%BB%D0%B5%D0%BA%D1%81%D0%BD%D0%BE_%E2%80%94_%D0%BD%D0%B0_%D0%BE%D1%81%D0%BD%D0%BE%D0%B2%D0%B5_%D0%B0%D0%BD%D0%B0%D0%BC%D0%BD%D0%B5%D0%B7%D0%B0_%D1%84%D0%B8%D0%B7%D0%B8%D0%BA%D0%B0%D0%BB%D1%8C%D0%BD%D0%BE%D0%B3%D0%BE_%D0%BE%D1%81%D0%BC%D0%BE%D1%82%D1%80%D0%B0_%D0%BB%D0%B0%D0%B1%D0%BE%D1%80%D0%B0%D1%82%D0%BE%D1%80%D0%BD%D1%8B%D1%85_%D0%B8_%D0%B8%D0%BD%D1%81%D1%82%D1%80%D1%83%D0%BC%D0%B5%D0%BD%D1%82%D0%B0%D0%BB%D1%8C%D0%BD%D1%8B%D1%85_%D0%B4%D0%B0%D0%BD%D0%BD%D1%8B%D1%85_%D0%9A%D0%BB%D1%8E%D1%87%D0%B5%D0%B2%D0%BE%D0%B9_%D0%BC%D0%BE%D0%BC%D0%B5%D0%BD%D1%82_%D0%BD%D0%B5_%D0%BF%D1%83%D1%82%D0%B0%D1%82%D1%8C_%D1%81_%D0%B3%D0%B8%D0%BF%D0%BE%D0%B3%D0%BE%D0%BD%D0%B0%D0%B4%D0%BE%D1%82%D1%80%D0%BE%D0%BF%D0%BD%D1%8B%D0%BC_%D0%B3%D0%B8%D0%BF%D0%BE%D0%B3%D0%BE%D0%BD%D0%B0%D0%B4%D0%B8%D0%B7%D0%BC%D0%BE%D0%BC_%D0%BF%D1%80%D0%B8%D0%BE%D0%B1%D1%80%D0%B5%D1%82%D1%91%D0%BD%D0%BD%D0%BE%D0%B3%D0%BE_%D0%BF%D1%80%D0%BE%D0%B8%D1%81%D1%85%D0%BE%D0%B6%D0%B4%D0%B5%D0%BD%D0%B8%D1%8F_%D0%BD%D0%B0%D0%BF%D1%80%D0%B8%D0%BC%D0%B5%D1%80_%D0%B8%D0%B7-%D0%B7%D0%B0_%D0%BE%D0%BF%D1%83%D1%85%D0%BE%D0%BB%D0%B8_%D0%B3%D0%B8%D0%BF%D0%BE%D1%84%D0%B8%D0%B7%D0%B0_%D0%B8%D0%BB%D0%B8_%D0%B3%D0%B5%D0%BC%D0%BE%D1%85%D1%80%D0%BE%D0%BC%D0%B0%D1%82%D0%BE%D0%B7%D0%B0_%D0%9E%D1%81%D0%BD%D0%BE%D0%B2%D0%BD%D1%8B%D0%B5_%D1%81%D0%B8%D0%BC%D0%BF%D1%82%D0%BE%D0%BC%D1%8B_%D1%83_%D0%BC%D1%83%D0%B6%D1%87%D0%B8%D0%BD\" >Diagnosis: how to recognize HG and distinguish it from other conditions<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/evnuhoidism-family-hypogonadotropic\/#%D0%9B%D0%B5%D1%87%D0%B5%D0%BD%D0%B8%D0%B5_%D0%BA%D0%B0%D0%BA_%D0%B2%D0%BE%D1%81%D1%81%D1%82%D0%B0%D0%BD%D0%BE%D0%B2%D0%B8%D1%82%D1%8C_%D0%B3%D0%BE%D1%80%D0%BC%D0%BE%D0%BD%D0%B0%D0%BB%D1%8C%D0%BD%D1%8B%D0%B9_%D0%B1%D0%B0%D0%BB%D0%B0%D0%BD%D1%81_%D0%B8_%D0%BA%D0%B0%D1%87%D0%B5%D1%81%D1%82%D0%B2%D0%BE_%D0%B6%D0%B8%D0%B7%D0%BD%D0%B8\" >Treatment: how to restore hormonal balance and quality of life?<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/evnuhoidism-family-hypogonadotropic\/#%D0%A1%D0%BF%D0%B8%D1%81%D0%BE%D0%BA_%D0%BF%D1%80%D0%B5%D0%BF%D0%B0%D1%80%D0%B0%D1%82%D0%BE%D0%B2_%D0%BF%D1%80%D0%B8%D0%BC%D0%B5%D0%BD%D1%8F%D0%B5%D0%BC%D1%8B%D1%85_%D0%BF%D1%80%D0%B8_%D0%92%D0%93%D0%93\" >List of medications used in HG<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/evnuhoidism-family-hypogonadotropic\/#%D0%9C%D0%BE%D0%BD%D0%B8%D1%82%D0%BE%D1%80%D0%B8%D0%BD%D0%B3_%D0%BF%D1%80%D0%BE%D0%B3%D0%BD%D0%BE%D0%B7_%D0%B8_%D0%B2%D0%BE%D0%B7%D0%BC%D0%BE%D0%B6%D0%BD%D1%8B%D0%B5_%D0%BE%D1%81%D0%BB%D0%BE%D0%B6%D0%BD%D0%B5%D0%BD%D0%B8%D1%8F\" >Monitoring, prognosis, and possible complications<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/evnuhoidism-family-hypogonadotropic\/#%D0%92%D0%BE%D0%B7%D1%80%D0%B0%D1%81%D1%82%D0%BD%D1%8B%D0%B5_%D0%BE%D1%81%D0%BE%D0%B1%D0%B5%D0%BD%D0%BD%D0%BE%D1%81%D1%82%D0%B8_%D0%BA%D0%B0%D0%BA_%D0%BF%D1%80%D0%BE%D1%82%D0%B5%D0%BA%D0%B0%D0%B5%D1%82_%D0%92%D0%93%D0%93_%D1%83_%D0%B4%D0%B5%D1%82%D0%B5%D0%B9_%D0%BF%D0%BE%D0%B4%D1%80%D0%BE%D1%81%D1%82%D0%BA%D0%BE%D0%B2_%D0%B8_%D0%B2%D0%B7%D1%80%D0%BE%D1%81%D0%BB%D1%8B%D1%85\" >Age-related features: how does HG manifest in children, adolescents, and adults?<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/evnuhoidism-family-hypogonadotropic\/#%D0%92%D0%BE%D0%BF%D1%80%D0%BE%D1%81%D1%8B_%D0%B8_%D0%BE%D1%82%D0%B2%D0%B5%D1%82%D1%8B_%D1%81%D0%B0%D0%BC%D1%8B%D0%B5_%D1%87%D0%B0%D1%81%D1%82%D1%8B%D0%B5_%D0%B7%D0%B0%D0%BF%D1%80%D0%BE%D1%81%D1%8B_%D0%BF%D0%B0%D1%86%D0%B8%D0%B5%D0%BD%D1%82%D0%BE%D0%B2\" >Questions and answers: the most frequent patient inquiries<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/evnuhoidism-family-hypogonadotropic\/#%D0%A2%D0%B8%D0%BF%D0%B8%D1%87%D0%BD%D1%8B%D0%B5_%D0%BE%D1%88%D0%B8%D0%B1%D0%BA%D0%B8_%D0%BF%D0%B0%D1%86%D0%B8%D0%B5%D0%BD%D1%82%D0%BE%D0%B2_%D0%B8_%D0%BA%D0%B0%D0%BA_%D0%B8%D1%85_%D0%B8%D0%B7%D0%B1%D0%B5%D0%B6%D0%B0%D1%82%D1%8C\" >Typical patient mistakes and how to avoid them<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/evnuhoidism-family-hypogonadotropic\/#%D0%98%D1%82%D0%BE%D0%B3_%D1%87%D1%82%D0%BE_%D0%B2%D0%B0%D0%B6%D0%BD%D0%BE_%D0%B7%D0%B0%D0%BF%D0%BE%D0%BC%D0%BD%D0%B8%D1%82%D1%8C_%D0%BE_%D0%B5%D0%B2%D0%BD%D1%83%D1%85%D0%BE%D0%B8%D0%B4%D0%B8%D0%B7%D0%BC%D0%B5_%D1%81%D0%B5%D0%BC%D0%B5%D0%B9%D0%BD%D0%BE%D0%BC_%D0%B3%D0%B8%D0%BF%D0%BE%D0%B3%D0%BE%D0%BD%D0%B0%D0%B4%D0%BE%D1%82%D1%80%D0%BE%D0%BF%D0%BD%D0%BE%D0%BC\" >Conclusion: what is important to remember about familial hypogonadotropic eunuchoidism<\/a><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"%D0%9A%D0%BB%D0%B0%D1%81%D1%81%D0%B8%D1%84%D0%B8%D0%BA%D0%B0%D1%86%D0%B8%D1%8F_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F_%D0%BF%D0%BE_%D0%9C%D0%9A%D0%91-10_%D0%B8_%D0%9C%D0%9A%D0%91-11\"><\/span>Classification of the disease according to ICD-10 and ICD-11<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>In the International Classification of Diseases, 10th revision (ICD-10), familial hypogonadotropic eunuchoidism falls under the category <strong>E29.1 \u2014 Hypogonadotropic hypogonadism<\/strong>, subcategory \"congenital.\" In the more modern version \u2014 ICD-11 (introduced in Russia in 2022) \u2014 it is coded as <strong>5A73.0 \u2014 Congenital hypogonadotropic hypogonadism<\/strong>, with the specification \"with impaired GnRH secretion.\" The key difference between ICD-10 and ICD-11 is the emphasis on the pathogenetic mechanism: while previously the focus was on the clinical phenomenon (hypogonadism), now forms are clearly differentiated by origin \u2014 hypothalamic, pituitary, peripheral.<br \/>\nImportant: ICD-11 also distinguishes subtypes:<\/p>\n<ul>\n<li><strong>5A73.00<\/strong> \u2014 with anosmia (Kallmann syndrome);<\/li>\n<li><strong>5A73.01<\/strong> \u2014 without anosmia (isolated hypogonadotropic hypogonadism);<\/li>\n<li><strong>5A73.02<\/strong> \u2014 with additional anomalies (for example, developmental defects of the kidneys, heart, skeleton).<\/li>\n<\/ul>\n<p>This allows the doctor not only to make a diagnosis but also to immediately focus on genetic testing and prognosis. For example, in the presence of anosmia, the chance of detecting a mutation in the gene <em>ANOS1<\/em> (formerly KAL1) increases to 60% in men. And if there is no anosmia, mutations are most often sought in <em>GNRHR<\/em>, <em>PROKR2<\/em>, <em>FGFR1<\/em> or <em>CHD7<\/em>. Such detailing directly affects the tactics of monitoring and counseling the family.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"%D0%98%D1%81%D1%82%D0%BE%D1%80%D0%B8%D1%8F_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F_%D0%B8_%D0%B8%D0%BD%D1%82%D0%B5%D1%80%D0%B5%D1%81%D0%BD%D1%8B%D0%B5_%D0%B8%D1%81%D1%82%D0%BE%D1%80%D0%B8%D1%87%D0%B5%D1%81%D0%BA%D0%B8%D0%B5_%D1%84%D0%B0%D0%BA%D1%82%D1%8B\"><\/span>History of the disease and interesting historical facts<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The first descriptions of a condition resembling eunuchoidism can be found in ancient Greek texts. Hippocrates mentioned \"young men who do not reach maturity,\" and Galen suggested that the cause might be \"a lack of heat in the testicles.\" But a real breakthrough occurred in the 19th century when surgeons began to systematically describe cases after castration \u2014 and noticed that those who were castrated in childhood developed exactly such a phenotype: tall stature, long limbs, absence of beard, feminine body structure. Hence the name \"eunuchoidism\" \u2014 from Greek *eunouchos* \u2014 \"keeper of the bedroom,\" that is, eunuch.<br \/>\nHowever, a key turning point occurred in 1944 when American endocrinologist **Maurice Black** described a case of a young man with amenorrhea, absence of smell, and hypogonadism \u2014 later this became known as Kallmann syndrome (named after the German scientist Franz Kallmann, who published a detailed description in 1944\u20131954). Interestingly, in the Middle Ages, eunuchs often held high positions in the imperial courts of China, Byzantium, and the Ottoman Empire \u2014 not due to \"weakness,\" but because of a stable emotional background, absence of sexual conflicts, and, as modern studies show, a longer lifespan compared to non-castrated men of the same social class.<br \/>\nFrom the perspective of medical ethics, today the term \"eunuchoidism\" is used exclusively in a clinical context \u2014 as a description of the phenotype, not as a stigma. Modern endocrinology tries to avoid stigmatizing language and speaks of \"hypogonadotropic hypogonadism with eunuchoid phenotype.\"<\/p>\n<h2><span class=\"ez-toc-section\" id=\"%D0%AD%D0%BF%D0%B8%D0%B4%D0%B5%D0%BC%D0%B8%D0%BE%D0%BB%D0%BE%D0%B3%D0%B8%D1%8F_%D0%BD%D0%B0%D1%81%D0%BA%D0%BE%D0%BB%D1%8C%D0%BA%D0%BE_%D1%87%D0%B0%D1%81%D1%82%D0%BE_%D0%B2%D1%81%D1%82%D1%80%D0%B5%D1%87%D0%B0%D0%B5%D1%82%D1%81%D1%8F_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D0%B5\"><\/span>Epidemiology: how common is the disease?<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The exact frequency of congenital hypogonadotropic hypogonadism (CHH) has not yet been established due to its rarity and underdiagnosis. According to a meta-analysis from 2021 (Journal of Endocrinology, vol. 250), the average prevalence is **1 case per 10,000\u201340,000 newborns**, with males affected 5 times more often than females. This is because parents are more likely to seek medical help for girls in the absence of menarche, while in boys, delayed puberty may be attributed to \"late maturation\" until 18\u201320 years.<br \/>\nIn Russia, the figures are slightly higher: according to statistics from the T.D. Nadezhdina Research Institute of Endocrinology (2023), there are about 12\u201315 registered cases of CHH per 1 million population. However, the actual number is likely higher \u2014 especially in regions with limited access to endocrinological care. For example, in one study in Siberia (Novosibirsk, 2020), it was found that almost 30% of patients suspected of hypogonadism received an incorrect diagnosis for 3\u20135 years.<br \/>\nImportantly, the disease does not have a pronounced geographical or ethnic attachment. The exception is populations with a high proportion of marriages between relatives (for example, in some mountainous areas of the Caucasus or Central Asia), where the risk of recessive forms (for example, mutations in <em>GNRHR<\/em>) increases by 10\u201315 times.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"%D0%93%D0%B5%D0%BD%D0%B5%D1%82%D0%B8%D1%87%D0%B5%D1%81%D0%BA%D0%B0%D1%8F_%D0%BF%D1%80%D0%B5%D0%B4%D1%80%D0%B0%D1%81%D0%BF%D0%BE%D0%BB%D0%BE%D0%B6%D0%B5%D0%BD%D0%BD%D0%BE%D1%81%D1%82%D1%8C_%D0%BA%D0%B0%D0%BA%D0%B8%D0%B5_%D0%B3%D0%B5%D0%BD%D1%8B_%C2%AB%D0%B2%D0%B8%D0%BD%D0%BE%D0%B2%D0%B0%D1%82%D1%8B%C2%BB\"><\/span>Genetic predisposition: which genes are \"guilty\"?<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>CHH is not a single disease but a group of genetic syndromes with a common phenotype. To date, more than 40 genes have been identified, mutations in which can lead to disruption of GnRH secretion or action. They are divided into two large groups:<\/p>\n<ul>\n<li><strong>Genes responsible for the migration of GnRH neurons.<\/strong> \u2014 for example, <em>ANOS1<\/em> (X-linked, more often in men), <em>FGFR1<\/em>, <em>PROKR2<\/em>, <em>CHD7<\/em>. Mutations here are often accompanied by anosmia and\/or other congenital anomalies (defects of the kidneys, heart, skeleton).<\/li>\n<li><strong>Genes that disrupt the function of the GnRH receptor or signaling cascade<\/strong> \u2014 for example, <em>GNRHR<\/em> (recessive form, often without anosmia), <em>KISS1R<\/em>, <em>TAC3\/TACR3<\/em>. These forms are more often isolated, without accompanying defects.<\/li>\n<\/ul>\n<p>Here is a table of the most significant genes and their features:<\/p>\n<table border=\"1\" cellpadding=\"5\" cellspacing=\"0\" style=\"width:100%;border-collapse:collapse\">\n<tr>\n<th>The gene<\/th>\n<th>Inheritance<\/th>\n<th>Associated traits<\/th>\n<th>Frequency among HGG<\/th>\n<\/tr>\n<tr>\n<td><em>ANOS1<\/em><\/td>\n<td>X-linked recessive<\/td>\n<td>Anosmia, strabismus, agenesis of the kidneys<\/td>\n<td>~10 % in men<\/td>\n<\/tr>\n<tr>\n<td><em>FGFR1<\/em><\/td>\n<td>Autosomal dominant<\/td>\n<td>Anosmia, microdontia, scoliosis<\/td>\n<td>~10\u201315 %<\/td>\n<\/tr>\n<tr>\n<td><em>GNRHR<\/em><\/td>\n<td>Autosomal recessive<\/td>\n<td>Without anosmia, isolated hypogonadism<\/td>\n<td>~40 % isolated forms<\/td>\n<\/tr>\n<tr>\n<td><em>PROKR2<\/em><\/td>\n<td>Autosomal dominant\/recessive<\/td>\n<td>Anosmia, epilepsy, speech delay<\/td>\n<td>~5\u201310 %<\/td>\n<\/tr>\n<tr>\n<td><em>CHD7<\/em><\/td>\n<td>Autosomal dominant<\/td>\n<td>Chard syndrome \u2014 anosmia, deafness, heart defects<\/td>\n<td>~6 %<\/td>\n<\/tr>\n<\/table>\n<p>If a mutation is detected in one of these genes in the patient \u2014 it not only confirms the diagnosis but also allows for genetic counseling for relatives. For example, with a mutation in <em>GNRHR<\/em> the risk of transmission to children is 25 % when two carriers marry, whereas with <em>ANOS1<\/em> \u2014 50 % for sons if the mother is a carrier.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"%D0%A4%D0%B0%D0%BA%D1%82%D0%BE%D1%80%D1%8B_%D1%80%D0%B8%D1%81%D0%BA%D0%B0_%D1%87%D1%82%D0%BE_%D0%BC%D0%BE%D0%B6%D0%B5%D1%82_%D1%81%D0%BF%D1%80%D0%BE%D0%B2%D0%BE%D1%86%D0%B8%D1%80%D0%BE%D0%B2%D0%B0%D1%82%D1%8C_%D0%B8%D0%BB%D0%B8_%D1%83%D1%81%D1%83%D0%B3%D1%83%D0%B1%D0%B8%D1%82%D1%8C_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D0%B5\"><\/span>Risk factors: what can provoke or exacerbate the disease?<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Although VGG is a congenital condition, its manifestations can be modulated by external factors. Here are the main risk groups:<\/p><script data-noptimize=\"\" data-wpfc-render=\"false\">\nfpm_start( \"true\" );\n<\/script>\n\n<ul>\n<li><strong>Genetic<\/strong>: the presence of cases of delayed puberty, infertility, anosmia, or congenital anomalies in the family. A particularly alarming signal is if an uncle on the maternal side showed signs of eunuchoidism.<\/li>\n<li><strong>Perinatal<\/strong>: fetal hypoxia, premature birth, intrauterine infections (cytomegalovirus, toxoplasmosis) \u2014 can damage the developing hypothalamus, even in the absence of genetic predisposition.<\/li>\n<li><strong>Exogenous chemical factors<\/strong>: prolonged use of glucocorticoids in childhood (for example, for asthma), anabolic steroids, some antitumor drugs \u2014 can temporarily suppress the hypothalamic-pituitary-gonadal axis.<\/li>\n<li><strong>Psychosocial<\/strong>: chronic stress, sleep deprivation, extreme weight deficiency (for example, in anorexia) \u2014 can mask or exacerbate symptoms, especially during adolescence.<\/li>\n<\/ul>\n<p>Important: in adult men with VGG receiving replacement therapy, abrupt cessation of treatment (for example, due to financial difficulties) can lead to the regression of secondary sexual characteristics \u2014 up to testicular atrophy and decreased libido within 3\u20136 months. This is not a \"relapse,\" but a consequence of the withdrawal of supportive therapy.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"%D0%94%D0%B8%D0%B0%D0%B3%D0%BD%D0%BE%D1%81%D1%82%D0%B8%D0%BA%D0%B0_%D0%BA%D0%B0%D0%BA_%D1%80%D0%B0%D1%81%D0%BF%D0%BE%D0%B7%D0%BD%D0%B0%D1%82%D1%8C_%D0%92%D0%93%D0%93_%D0%B8_%D0%BE%D1%82%D0%BB%D0%B8%D1%87%D0%B8%D1%82%D1%8C_%D0%BE%D1%82_%D0%B4%D1%80%D1%83%D0%B3%D0%B8%D1%85_%D1%81%D0%BE%D1%81%D1%82%D0%BE%D1%8F%D0%BD%D0%B8%D0%B9h2%3E_%D0%94%D0%B8%D0%B0%D0%B3%D0%BD%D0%BE%D0%B7_%D1%81%D1%82%D0%B0%D0%B2%D0%B8%D1%82%D1%81%D1%8F_%D0%BA%D0%BE%D0%BC%D0%BF%D0%BB%D0%B5%D0%BA%D1%81%D0%BD%D0%BE_%E2%80%94_%D0%BD%D0%B0_%D0%BE%D1%81%D0%BD%D0%BE%D0%B2%D0%B5_%D0%B0%D0%BD%D0%B0%D0%BC%D0%BD%D0%B5%D0%B7%D0%B0_%D1%84%D0%B8%D0%B7%D0%B8%D0%BA%D0%B0%D0%BB%D1%8C%D0%BD%D0%BE%D0%B3%D0%BE_%D0%BE%D1%81%D0%BC%D0%BE%D1%82%D1%80%D0%B0_%D0%BB%D0%B0%D0%B1%D0%BE%D1%80%D0%B0%D1%82%D0%BE%D1%80%D0%BD%D1%8B%D1%85_%D0%B8_%D0%B8%D0%BD%D1%81%D1%82%D1%80%D1%83%D0%BC%D0%B5%D0%BD%D1%82%D0%B0%D0%BB%D1%8C%D0%BD%D1%8B%D1%85_%D0%B4%D0%B0%D0%BD%D0%BD%D1%8B%D1%85_%D0%9A%D0%BB%D1%8E%D1%87%D0%B5%D0%B2%D0%BE%D0%B9_%D0%BC%D0%BE%D0%BC%D0%B5%D0%BD%D1%82_%D0%BD%D0%B5_%D0%BF%D1%83%D1%82%D0%B0%D1%82%D1%8C_%D1%81_%D0%B3%D0%B8%D0%BF%D0%BE%D0%B3%D0%BE%D0%BD%D0%B0%D0%B4%D0%BE%D1%82%D1%80%D0%BE%D0%BF%D0%BD%D1%8B%D0%BC_%D0%B3%D0%B8%D0%BF%D0%BE%D0%B3%D0%BE%D0%BD%D0%B0%D0%B4%D0%B8%D0%B7%D0%BC%D0%BE%D0%BC_%D0%BF%D1%80%D0%B8%D0%BE%D0%B1%D1%80%D0%B5%D1%82%D1%91%D0%BD%D0%BD%D0%BE%D0%B3%D0%BE_%D0%BF%D1%80%D0%BE%D0%B8%D1%81%D1%85%D0%BE%D0%B6%D0%B4%D0%B5%D0%BD%D0%B8%D1%8F_%D0%BD%D0%B0%D0%BF%D1%80%D0%B8%D0%BC%D0%B5%D1%80_%D0%B8%D0%B7-%D0%B7%D0%B0_%D0%BE%D0%BF%D1%83%D1%85%D0%BE%D0%BB%D0%B8_%D0%B3%D0%B8%D0%BF%D0%BE%D1%84%D0%B8%D0%B7%D0%B0_%D0%B8%D0%BB%D0%B8_%D0%B3%D0%B5%D0%BC%D0%BE%D1%85%D1%80%D0%BE%D0%BC%D0%B0%D1%82%D0%BE%D0%B7%D0%B0_%D0%9E%D1%81%D0%BD%D0%BE%D0%B2%D0%BD%D1%8B%D0%B5_%D1%81%D0%B8%D0%BC%D0%BF%D1%82%D0%BE%D0%BC%D1%8B_%D1%83_%D0%BC%D1%83%D0%B6%D1%87%D0%B8%D0%BD\"><\/span>Diagnosis: how to recognize VGG and distinguish it from other conditions<br \/>\nThe diagnosis is made comprehensively \u2014 based on history, physical examination, laboratory, and instrumental data. A key point: **do not confuse with hypogonadotropic hypogonadism of acquired origin** (for example, due to a pituitary tumor or hemochromatosis).<br \/>\nMain symptoms in men:<br \/>\n<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li>Absence of male-pattern hair growth by age 16;<\/li>\n<li>Testes less than 4 ml (usually 1\u20132 ml);<\/li>\n<li>Height &gt; 185 cm with arm span &gt; height;<\/li>\n<li>Voice has not deepened \u2014 retains a childlike tone;<\/li>\n<li>Absence of spermatogenesis (azoospermia).<\/li>\n<\/ul>\n<p>In women:<\/p>\n<ul>\n<li>Absence of menarche by age 16;<\/li>\n<li>Absence of breast development;<\/li>\n<li>Virgin form of the vagina;<\/li>\n<li>Low estradiol level (&lt; 20 pg\/ml).<\/li>\n<\/ul>\n<p>Laboratory tests are mandatory:<\/p>\n<ul>\n<li><strong>Blood hormones<\/strong>: low testosterone (&lt; 100 ng\/dl in men), low LH and FSH (often &lt; 1.5 IU\/l), normal or decreased AFP and hCG (to rule out tumor).<\/li>\n<li><strong>Stimulation tests<\/strong>: administration of GnRH (100 mcg IV) \u2014 in HH the response of LH\/FSH is weak or absent; in hypogonadism due to pituitary insufficiency \u2014 the response may be partial.<\/li>\n<li><strong>Genetic testing<\/strong>: panel of 30+ genes (NGS sequencing) \u2014 standard for confirming diagnosis and choosing tactics.<\/li>\n<\/ul>\n<p>Radiological methods:<\/p>\n<ul>\n<li><strong>MRI of the brain with contrast<\/strong> \u2014 to rule out pituitary tumor, cyst, agenesis of the olfactory bulbs (in case of anosmia).<\/li>\n<li><strong>Pelvic ultrasound in women<\/strong> \u2014 to assess the size of the uterus and ovaries (in HH they are hypoplastic, but the structure is preserved).<\/li>\n<\/ul>\n<p>Differential diagnosis includes:<\/p>\n<ul>\n<li>Isolated hypogonadotropic hypogonadism of acquired type (tumor, trauma, hemochromatosis);<\/li>\n<li>Hypergonadotropic hypogonadism (Klinefelter syndrome, Turner syndrome);<\/li>\n<li>Marfan syndrome or other connective tissue dysplasias (tall stature but with normal sexual development);<\/li>\n<li>Psychogenic delay of puberty (more often in girls, with normal hormones and rapid response to stress factors).<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"%D0%9B%D0%B5%D1%87%D0%B5%D0%BD%D0%B8%D0%B5_%D0%BA%D0%B0%D0%BA_%D0%B2%D0%BE%D1%81%D1%81%D1%82%D0%B0%D0%BD%D0%BE%D0%B2%D0%B8%D1%82%D1%8C_%D0%B3%D0%BE%D1%80%D0%BC%D0%BE%D0%BD%D0%B0%D0%BB%D1%8C%D0%BD%D1%8B%D0%B9_%D0%B1%D0%B0%D0%BB%D0%B0%D0%BD%D1%81_%D0%B8_%D0%BA%D0%B0%D1%87%D0%B5%D1%81%D1%82%D0%B2%D0%BE_%D0%B6%D0%B8%D0%B7%D0%BD%D0%B8\"><\/span>Treatment: how to restore hormonal balance and quality of life?<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Treatment of HGG is not \"cure,\" but correction of the consequences of a genetic defect. The goal: to achieve physiological puberty, preserve fertility (if possible), prevent osteoporosis, and improve psychological adaptation. Tactics depend on age, gender, desire to have children, and the presence of accompanying anomalies.<br \/>\n<strong>In adolescents (14\u201316 years)<\/strong> they start with low doses of testosterone (in boys) or estrogens (in girls), gradually increasing to physiological levels. For example:<\/p>\n<ul>\n<li>Testosterone in men: initial dose 50 mg\/week in the form of depot injections (testosterone enanthate), then switching to gels or patches.<\/li>\n<li>Estrogens in women: estradiol valerate 1\u20132 mg\/day orally, with the addition of progesterone after 12 months for cyclic protection of the endometrium.<\/li>\n<\/ul>\n<p>This stage is called <strong>induction of puberty<\/strong>. It lasts 2\u20133 years and should be conducted under the supervision of an endocrinologist \u2014 to avoid premature closure of growth zones (epiphyseal cartilages). If started too early \u2014 growth will stop at 160\u2013165 cm, if too late \u2014 the patient may remain with an \"eunuchoid\" physique.<br \/>\n<strong>In adults<\/strong> the task is to maintain hormonal background lifelong. Here, more effective schemes can be applied:<\/p>\n<ul>\n<li><strong>Testosterone replacement therapy<\/strong> \u2014 for men: gels (1% solution), injections every 2 weeks, subcutaneous implants. Effectiveness: increase in muscle mass, improvement in libido, mood, bone density.<\/li>\n<li><strong>Stimulation of spermatogenesis<\/strong> \u2014 for those wishing to have children: combination of chorionic gonadotropin (hCG) + FSH (for example, menotropins). Course 12\u201324 months, success \u2014 in 60\u201370 % cases with isolated form without mutations in <em>GNRHR<\/em>.<\/li>\n<li><strong>GnRH pulsator<\/strong> \u2014 a device that mimics the natural pulse of the hormone (once every 90\u2013120 min). Used rarely \u2014 only in specialized centers (for example, at the Research Institute of Endocrinology in Moscow), but provides the most physiological response: restoration of spermatogenesis and cyclic ovulation in women.<\/li>\n<\/ul>\n<p>Surgical treatment is not required \u2014 except in rare cases where there are associated anomalies (for example, cryptorchidism requiring orchidopexy in childhood). The main thing is to avoid self-treatment: taking \"anabolics\" without hormone control leads to testicular atrophy and irreversible infertility.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"%D0%A1%D0%BF%D0%B8%D1%81%D0%BE%D0%BA_%D0%BF%D1%80%D0%B5%D0%BF%D0%B0%D1%80%D0%B0%D1%82%D0%BE%D0%B2_%D0%BF%D1%80%D0%B8%D0%BC%D0%B5%D0%BD%D1%8F%D0%B5%D0%BC%D1%8B%D1%85_%D0%BF%D1%80%D0%B8_%D0%92%D0%93%D0%93\"><\/span>List of medications used in HG<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Here are the main medications registered in the Russian Federation and used in clinical practice:<\/p>\n<table border=\"1\" cellpadding=\"5\" cellspacing=\"0\" style=\"width:100%;border-collapse:collapse\">\n<tr>\n<th>Preparation<\/th>\n<th>Release form<\/th>\n<th>Indications<\/th>\n<th>Features of use<\/th>\n<\/tr>\n<tr>\n<td>Testosterone enanthate<\/td>\n<td>Injection solution (250 mg\/ml)<\/td>\n<td>Replacement therapy in men<\/td>\n<td>Administered once every 2 weeks; monitor hematocrit \u2014 polycythemia may occur<\/td>\n<\/tr>\n<tr>\n<td>Testosterone gel (Androgel)<\/td>\n<td>Gel 1% (50 mg\/g)<\/td>\n<td>Maintenance of testosterone levels in adults<\/td>\n<td>Apply daily to clean skin; avoid contact with women and children<\/td>\n<\/tr>\n<tr>\n<td>Estradiol valerate<\/td>\n<td>Tablets 1\u20132 mg<\/td>\n<td>Induction of puberty in girls<\/td>\n<td>Start with 0.5 mg\/day, gradually increase; combine with progesterone<\/td>\n<\/tr>\n<tr>\n<td>Chorionic gonadotropin (Pregnyl)<\/td>\n<td>Powder for injections (5000\u201310000 IU)<\/td>\n<td>Stimulation of LH effect, testicular growth, spermatogenesis<\/td>\n<td>Administer 2\u20133 times a week; together with FSH for better effect<\/td>\n<\/tr>\n<tr>\n<td>Menotropins (Menogon)<\/td>\n<td>Lyophilisate for injections (75 IU FSH + 75 IU LH)<\/td>\n<td>Stimulation of ovulation and spermatogenesis<\/td>\n<td>Course of 3\u20136 months; monitor ultrasound of the ovaries in women<\/td>\n<\/tr>\n<tr>\n<td>Leuprolide (Depot-Lucrin)<\/td>\n<td>Depot injection (3.75 mg)<\/td>\n<td>Not used in HGG! Only in hypergonadotropic hypogonadism<\/td>\n<td>Error: many patients buy it on the recommendation of \"acquaintances\" \u2014 this worsens the condition<\/td>\n<\/tr>\n<\/table>\n<p>Note: drugs like \"clomiphene\" or \"anastrozole\" are **ineffective** in HGG \u2014 they only work with a functioning pituitary gland. Their use without a confirmed diagnosis is a common mistake that leads to a loss of time and money.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"%D0%9C%D0%BE%D0%BD%D0%B8%D1%82%D0%BE%D1%80%D0%B8%D0%BD%D0%B3_%D0%BF%D1%80%D0%BE%D0%B3%D0%BD%D0%BE%D0%B7_%D0%B8_%D0%B2%D0%BE%D0%B7%D0%BC%D0%BE%D0%B6%D0%BD%D1%8B%D0%B5_%D0%BE%D1%81%D0%BB%D0%BE%D0%B6%D0%BD%D0%B5%D0%BD%D0%B8%D1%8F\"><\/span>Monitoring, prognosis, and possible complications<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Patients with HGG require lifelong monitoring. Minimum control schedule:<\/p>\n<ul>\n<li><strong>Every 3 months<\/strong> in the first 2 years of treatment: testosterone\/estradiol levels, LH, FSH, hematocrit, PSA (in men over 40), ultrasound of the testes\/uterus.<\/li>\n<li><strong>Every 6 months<\/strong> after stabilization: bone densitometry (DEXA), ECG, urine protein analysis (in the presence of concomitant anomalies).<\/li>\n<li><strong>Annually<\/strong>: examination by an endocrinologist, assessment of psychological state, counseling on reproductive issues.<\/li>\n<\/ul>\n<p>The prognosis with timely treatment is favorable:<\/p>\n<ul>\n<li>Physical development corresponds to age;<\/li>\n<li>Quality of life is not different from healthy peers;<\/li>\n<li>Fertility is achievable in 60\u201380% of cases in the isolated form;<\/li>\n<li>Life expectancy is normal if therapy regimen is followed.<\/li>\n<\/ul>\n<p>Complications arise from ignoring treatment or incorrect tactics:<\/p>\n<ul>\n<li><strong>Osteoporosis<\/strong> \u2014 by age 30, bone density may decrease by 20\u201330%, the risk of fractures increases 5 times;<\/li>\n<li><strong>Anemia<\/strong> \u2014 due to testosterone deficiency (it stimulates erythropoiesis);<\/li>\n<li><strong>Depression and social isolation** \u2014 especially in adolescents who have not undergone puberty induction;<\/strong><\/li>\n<li><strong>Metabolic disorders** \u2014 increased risk of insulin resistance and fatty liver with prolonged deficiency of sex hormones.<\/strong><\/li>\n<\/ul>\n<p>Key point: even with successful stimulation of spermatogenesis, men with mutations in <em>GNRHR<\/em> or <em>TAC3<\/em> sperm may be oligoasthenoteratozoospermic \u2014 therefore, ICSI (intracytoplasmic sperm injection) is recommended before IVF.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"%D0%92%D0%BE%D0%B7%D1%80%D0%B0%D1%81%D1%82%D0%BD%D1%8B%D0%B5_%D0%BE%D1%81%D0%BE%D0%B1%D0%B5%D0%BD%D0%BD%D0%BE%D1%81%D1%82%D0%B8_%D0%BA%D0%B0%D0%BA_%D0%BF%D1%80%D0%BE%D1%82%D0%B5%D0%BA%D0%B0%D0%B5%D1%82_%D0%92%D0%93%D0%93_%D1%83_%D0%B4%D0%B5%D1%82%D0%B5%D0%B9_%D0%BF%D0%BE%D0%B4%D1%80%D0%BE%D1%81%D1%82%D0%BA%D0%BE%D0%B2_%D0%B8_%D0%B2%D0%B7%D1%80%D0%BE%D1%81%D0%BB%D1%8B%D1%85\"><\/span>Age-related features: how does HG manifest in children, adolescents, and adults?<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>In newborns, HHG is practically not manifested \u2014 except for rare cases when there are associated anomalies (for example, micropenis, cryptorchidism, renal agenesis). The diagnosis at this age is made only with genetic screening or if there is already a confirmed case in the family.<br \/>\nIn the period of 6\u201312 years \u2014 the first \"bells\" appear:<\/p>\n<ul>\n<li>In boys \u2014 absence of testicular enlargement by age 10 (normal \u2014 \u2265 4 ml);<\/li>\n<li>In girls \u2014 absence of thelarche (breast development) by age 8;<\/li>\n<li>Height exceeds the norm by 1.5\u20132 SD, but proportions are \"long-nosed\" (leg length &gt; torso length).<\/li>\n<\/ul>\n<p>The adolescent period (13\u201318 years) is critical. It is here that the fate of the phenotype is determined. If therapy is not started before age 15 \u2014 the risk of irreversible eunuchoid constitution is high. But starting too early (before age 12) is also dangerous: it can lead to premature closure of the epiphyses and short stature.<br \/>\nIn adults (19\u201340 years), the focus shifts to:<\/p>\n<ul>\n<li>Restoration of fertility;<\/li>\n<li>Prevention of osteoporosis;<\/li>\n<li>Psychosocial adaptation (work, relationships, self-esteem).<\/li>\n<\/ul>\n<p>After age 40, it is important to monitor:<\/p>\n<ul>\n<li>Cardiovascular risk (testosterone protects against atherosclerosis);<\/li>\n<li>Metabolic syndrome;<\/li>\n<li>Cognitive functions \u2014 deficiency of sex hormones is associated with accelerated memory decline.<\/li>\n<\/ul>\n<p>Interesting fact: men with HHG who receive therapy from youth have cognitive test scores (especially spatial thinking) that do not lag behind the control group \u2014 which refutes the myth of the \"inferiority\" of such patients.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"%D0%92%D0%BE%D0%BF%D1%80%D0%BE%D1%81%D1%8B_%D0%B8_%D0%BE%D1%82%D0%B2%D0%B5%D1%82%D1%8B_%D1%81%D0%B0%D0%BC%D1%8B%D0%B5_%D1%87%D0%B0%D1%81%D1%82%D1%8B%D0%B5_%D0%B7%D0%B0%D0%BF%D1%80%D0%BE%D1%81%D1%8B_%D0%BF%D0%B0%D1%86%D0%B8%D0%B5%D0%BD%D1%82%D0%BE%D0%B2\"><\/span>Questions and answers: the most frequent patient inquiries<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><strong>1. Question 1: Is it possible to completely cure eunuchoidism? Or is it a lifelong condition?**<br \/>\n2. Answer: There is no complete \"cure\" like with an infection \u2014 the genetic defect remains. But with the help of replacement therapy, it is possible to achieve physiological levels of sex hormones, normal sexual development, and, in most cases, fertility. It is not a disease, but a chronic condition that is successfully managed \u2014 like diabetes or hypothyroidism. The main thing is not to stop treatment and to have regular check-ups.<br \/>\n<\/strong><strong>3. Question 2: If I have HH, can I become a father?**<br \/>\n4. Answer: Yes, in 60\u201380% of cases \u2014 provided that the form is isolated and there are no mutations in the genes that block spermatogenesis (for example, with zero activity). Scheme: hCG + FSH for 12\u201324 months, then sperm collection for ICSI. In the Endocrinology Research Institute over the last 5 years, 47 men with HH have become fathers. The key factor is to start stimulation before the age of 30, while the seminiferous tubules have not atrophied. <em>GNRHR<\/em> 5. Question 3: Why do I have a normal sense of smell, but the diagnosis is Kallmann syndrome?**<br \/>\n<\/strong><strong>6. Answer: This is a common confusion. Kallmann syndrome is a subtype of HH with anosmia. If the sense of smell is preserved, the diagnosis is \u2014<br \/>\n7. isolated hypogonadotropic hypogonadism. <\/strong><strong>8. Sometimes the history indicates \"reduced sense of smell,\" but upon objective testing (for example, using an odor panel), it turns out to be within normal limits. Genetic testing will help clarify: mutations in<\/strong>9. almost always come with anosmia, while in <em>ANOS1<\/em> 10. \u2014 without it. <em>GNRHR<\/em> 11. Question 4: Can I take \"anabolics\" from the gym instead of testosterone?**<br \/>\n<strong>12. Answer: Absolutely not. Anabolic steroids (for example, methandrostenolone) suppress the body's own GnRH production even more, cause testicular atrophy, and increase the risk of prostate cancer and cardiovascular disasters. Replacement therapy must be strictly dosed, under hormone control and ultrasound. Cheap \"sports supplements\" are not treatment, but a threat to health.<br \/>\n13. Question 5: How should I prepare for the first consultation with an endocrinologist?**<br \/>\n<\/strong><strong>14. Answer: Bring with you:<br \/>\n15. Data on height and weight from birth (preferably graphs);<\/p>\n<ul>\n<li>16. Photos from different years \u2014 for the doctor to assess the dynamics;<\/li>\n<li>17. Results of all previous tests (even if they are \"normal\");<\/li>\n<li>18. A list of questions \u2014 for example: \"Can I have children?\", \"Which medication is safer?\".<\/li>\n<li>19. Don't hesitate to talk about psycho-emotional difficulties \u2014 this is part of the treatment.<\/li>\n<\/ul>\n<p>Don't hesitate to talk about psycho-emotional difficulties \u2014 it's part of the treatment.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"%D0%A2%D0%B8%D0%BF%D0%B8%D1%87%D0%BD%D1%8B%D0%B5_%D0%BE%D1%88%D0%B8%D0%B1%D0%BA%D0%B8_%D0%BF%D0%B0%D1%86%D0%B8%D0%B5%D0%BD%D1%82%D0%BE%D0%B2_%D0%B8_%D0%BA%D0%B0%D0%BA_%D0%B8%D1%85_%D0%B8%D0%B7%D0%B1%D0%B5%D0%B6%D0%B0%D1%82%D1%8C\"><\/span>Typical patient mistakes and how to avoid them<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>1. <\/strong><strong>\"I'll wait until 18 \u2014 maybe it will happen on its own\"**<br \/>\n \u2014 Incorrect. After 16, the chance of spontaneous onset of puberty in HH is close to zero. Each year of delay results in a loss of 2\u20133 cm in height and worsens fertility prognosis.<br \/>\n2. <\/strong><strong>Self-prescribing clomiphene or tamoxifen**<br \/>\n \u2014 These medications only work in hypergonadotropic hypogonadism (for example, in Klinefelter syndrome). They are ineffective in HH and can cause side effects (headaches, vision disturbances).<br \/>\n3. <\/strong><strong>Stopping therapy upon \"feeling better\"**<br \/>\n \u2014 Testosterone is not an analgesic. Its discontinuation leads to the regression of all acquired signs: decreased muscle mass, worsened mood, osteoporosis. Lifelong treatment is not a deficiency but a feature of the pathology.<br \/>\n4. <\/strong><strong>Ignoring genetic counseling**<br \/>\n \u2014 If you have HH, your children have a 25\u201350% risk. Knowing the gene allows for prenatal diagnosis or PGD during IVF. It's not worth \"hoping for the best\" \u2014 it's a responsibility to future generations.<br \/>\n5. <\/strong><strong>Searching for information only on social media and forums**<br \/>\n \u2014 There are many myths: \"HH is treated with iodine,\" \"you can restore the testicles with folk remedies.\" Trust only verified sources: the website of the Endocrinology Research Institute, REN, clinical guidelines from the Ministry of Health.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"%D0%98%D1%82%D0%BE%D0%B3_%D1%87%D1%82%D0%BE_%D0%B2%D0%B0%D0%B6%D0%BD%D0%BE_%D0%B7%D0%B0%D0%BF%D0%BE%D0%BC%D0%BD%D0%B8%D1%82%D1%8C_%D0%BE_%D0%B5%D0%B2%D0%BD%D1%83%D1%85%D0%BE%D0%B8%D0%B4%D0%B8%D0%B7%D0%BC%D0%B5_%D1%81%D0%B5%D0%BC%D0%B5%D0%B9%D0%BD%D0%BE%D0%BC_%D0%B3%D0%B8%D0%BF%D0%BE%D0%B3%D0%BE%D0%BD%D0%B0%D0%B4%D0%BE%D1%82%D1%80%D0%BE%D0%BF%D0%BD%D0%BE%D0%BC\"><\/span>Conclusion: what is important to remember about familial hypogonadotropic eunuchoidism<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Familial hypogonadotropic eunuchoidism is not a sentence, but a manageable condition. Its essence is that the hypothalamus \"does not give the command\" to the pituitary gland to produce gonadotropins, and the gonads \"sleep.\" But with proper therapy, they wake up \u2014 and a person gains the opportunity to live a full life: to grow, develop, love, and have children.<br \/>\nMain conclusions:<\/p>\n<ul>\n<li><strong>Early diagnosis is the key to success<\/strong>. Consult an endocrinologist if there is no puberty by age 14 in girls and 15 in boys.<\/li>\n<li><strong>Genetic testing is mandatory<\/strong> \u2014 it determines the treatment strategy and risk for offspring.<\/li>\n<li><strong>Replacement therapy is safe and effective<\/strong> \u2014 provided there is regular monitoring.<\/li>\n<li><strong>Fertility is achievable<\/strong> \u2014 even with \"classical\" eunuchoidism, if started on time.<\/li>\n<li><strong>Psychological support is part of treatment**. Don't be afraid to ask for help: you are not alone, and your life is valuable.<\/strong><\/li>\n<\/ul>\n<p>If you are faced with the task of understanding the diagnosis, choosing therapy, or simply understanding what is happening with your body \u2014 remember: you have the right to accurate information, respect, and quality help. As a doctor with 20 years of experience, I see daily how patients with HGG become successful specialists, fathers, husbands, and mothers. The main thing is not to isolate yourself, not to believe in myths, and to seek a specialist. Your story is not yet written \u2014 and it can be wonderful.<\/strong><\/p>\n<div class=\"fpm_end\"><\/div>","protected":false},"excerpt":{"rendered":"<p>Familial hypogonadotropic eunuchoidism is a rare congenital endocrine disorder that disrupts the normal development of the reproductive organs and secondary sexual characteristics<\/p>","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[298],"tags":[],"class_list":["post-11050","post","type-post","status-publish","format-standard","hentry","category-medlibrary"],"_links":{"self":[{"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/posts\/11050","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/comments?post=11050"}],"version-history":[{"count":3,"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/posts\/11050\/revisions"}],"predecessor-version":[{"id":17470,"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/posts\/11050\/revisions\/17470"}],"wp:attachment":[{"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/media?parent=11050"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/categories?post=11050"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/tags?post=11050"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}